Targeted combo aims at tough lymphoma subtype
NCT ID NCT07677813
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, followed by orelabrutinib alone as maintenance therapy. The study tracks how long people live without the cancer worsening and monitors side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- orelabrutinib combined with R-CHOP or POLA-R-CHP chemotherapy
- What this could lead to
- If successful, this approach could offer a more effective treatment option for people with a specific genetic subtype of aggressive lymphoma.
- What could go wrong
- This is an early-phase, single-center study with a small number of participants, so results may not apply broadly. The drug combination may cause side effects, and the trial may not show a clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- New drug cocktail aims to outsmart aggressive blood cancer